[go: up one dir, main page]

WO2004029280A3 - Anti-hla assay and methods - Google Patents

Anti-hla assay and methods Download PDF

Info

Publication number
WO2004029280A3
WO2004029280A3 PCT/US2003/030096 US0330096W WO2004029280A3 WO 2004029280 A3 WO2004029280 A3 WO 2004029280A3 US 0330096 W US0330096 W US 0330096W WO 2004029280 A3 WO2004029280 A3 WO 2004029280A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
hla
hla assay
assay
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/030096
Other languages
French (fr)
Other versions
WO2004029280A2 (en
Inventor
Rico Buchli
William H Hildebrand
Christopher Giberson
Rod Vangundy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/000243 external-priority patent/WO2003057852A2/en
Priority claimed from US10/337,161 external-priority patent/US20060276629A9/en
Application filed by Individual filed Critical Individual
Priority to CA002539622A priority Critical patent/CA2539622A1/en
Priority to AU2003270876A priority patent/AU2003270876A1/en
Publication of WO2004029280A2 publication Critical patent/WO2004029280A2/en
Publication of WO2004029280A3 publication Critical patent/WO2004029280A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates generally to anti-HLA assay methodologies utilizing functionally active, individual soluble HLA molecules that are isolated and purified substantially away from other proteins.
PCT/US2003/030096 2002-09-24 2003-09-24 Anti-hla assay and methods Ceased WO2004029280A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002539622A CA2539622A1 (en) 2002-09-24 2003-09-24 Anti-hla assay and methods
AU2003270876A AU2003270876A1 (en) 2002-09-24 2003-09-24 Anti-hla assay and methods

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US41384202P 2002-09-24 2002-09-24
US60/413,842 2002-09-24
PCT/US2003/000243 WO2003057852A2 (en) 2001-12-18 2003-01-02 Purification and characterization of hla proteins
USPCT/US03/00243 2003-01-02
US10/337,161 US20060276629A9 (en) 1999-12-17 2003-01-02 Purification and characterization of soluble human HLA proteins
US10/337,161 2003-01-02

Publications (2)

Publication Number Publication Date
WO2004029280A2 WO2004029280A2 (en) 2004-04-08
WO2004029280A3 true WO2004029280A3 (en) 2004-07-15

Family

ID=32684708

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/030096 Ceased WO2004029280A2 (en) 2002-09-24 2003-09-24 Anti-hla assay and methods

Country Status (2)

Country Link
AU (1) AU2003270876A1 (en)
WO (1) WO2004029280A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173597B2 (en) 2007-11-09 2012-05-08 Baxter International Inc. Modified recombinant factor VIII and von Willebrand factor and methods of use

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012019534B1 (en) * 2010-02-17 2021-07-20 One Lambda, Inc METHOD FOR PREPARING A COMPOSITION COMPRISING AT LEAST 90% NATURAL HUMAN LEUKOCYTE ANTIGENS AND MAXIMUM 10% DENATURATED LEUKOCYTE ANTIGENS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255073B1 (en) * 1995-03-08 2001-07-03 The Scripps Research Institute Antigen presenting system and methods for activation of T-cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255073B1 (en) * 1995-03-08 2001-07-03 The Scripps Research Institute Antigen presenting system and methods for activation of T-cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PRILLIMAN K.R. ET AL.: "HLA-B15 peptide ligands are preferentially anchored at their C termini", JOURNAL OF IMMUNOLOGY, vol. 162, 1999, pages 7277 - 7284, XP002966691 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173597B2 (en) 2007-11-09 2012-05-08 Baxter International Inc. Modified recombinant factor VIII and von Willebrand factor and methods of use

Also Published As

Publication number Publication date
AU2003270876A8 (en) 2004-04-19
WO2004029280A2 (en) 2004-04-08
AU2003270876A1 (en) 2004-04-19

Similar Documents

Publication Publication Date Title
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
WO2004099249A3 (en) Optimized fc variants and methods for their generation
EP1553975B8 (en) Optimized fc variants and methods for their generation
WO2001064920A3 (en) Hybrid expression of neisserial proteins
WO2003056336A3 (en) Improved structured-functional bonding matrices for biomolecules
ID23374A (en) HALOGENOPIRIMIDIN
WO2001034646A3 (en) Recombinant gelatins
WO2006017274A3 (en) Systems and methods for sample modification using fluidic chambers
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
TW200612945A (en) Aerosol suspension formulations containing TG 227 ea as propellant
GB0100513D0 (en) Process
WO2002026968A3 (en) Antisense iap nucleic acids and uses thereof
WO2003025781A3 (en) Router
WO2005047494A3 (en) Haematopoietic stem cells suitable for transplantation, their preparation and pharmaceutical compositions comprising them
WO2004087735A3 (en) Proteolytic and covalent antibodies
WO2003074546A3 (en) Streptavidin-binding peptide
WO2005000888A3 (en) NOVEL β-ACTIN AND RPS21 PROMOTERS AND USES THEREOF
WO2003099192A8 (en) Bis-aromatic alkanols
WO2001098367A3 (en) Neuroactive peptides for treatment of hypoxia and related conditions
WO2004007664A3 (en) Nucleic acid vectors
WO2005087793A3 (en) Immunostimulatory compositions and uses thereof
WO2001036453A3 (en) Ny-eso-1 nanopeptide derivatives, and uses thereof
HK1046925A1 (en) Mage-a12 antigenic peptides and uses thereof
AU7216498A (en) Inhibitors of the urokinase receptor
WO2004029280A3 (en) Anti-hla assay and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 2539622

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP